• Vaccine Name: AH-PB
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: AH fusion proteins genetically linking Ag85A (FbpA) and HspX (Liang et al., 2022).
• FbpA (Ag85A) gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Liang et al., 2022).
  • Detailed Gene Information: Click Here.
• hspX gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Liang et al., 2022).
  • Detailed Gene Information: Click Here.
• Adjuvant: poly(I:C) vaccine adjuvant
  • Adjuvant name: poly(I:C) vaccine adjuvant
  • VO adjuvant ID: VO_0001332
  • Description: Poly(I:C) is used in this AH-PB vaccine to enhance innate immune activation and promote Th1/Th17-biased cellular and mucosal immune responses (Liang et al., 2022).
• Preparation: Fusion genes (Ag85A–HspX) were cloned, expressed recombinantly, and purified. Proteins were formulated with Poly I:C (± β-defensin-5) (Liang et al., 2022).
• Immunization Route: Nasal spray

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Mice were immunized intranasally with AH-PBfusion proteins formulated with poly(I:C) in a prime–boost regimen, with booster immunizations administered at defined intervals (Liang et al., 2022).
• Challenge Protocol: Vaccinated C57BL/6 mice were intranasally challenged with a low dose (~100 CFU) of Mycobacterium bovis, and protection was assessed by bacterial burden and lung pathology (Liang et al., 2022).
• Description: In a C57BL/6 mouse model, the vaccine induced robust cellular and mucosal immune responses and conferred significant protection against Mycobacterium bovis infection (Liang et al., 2022).
• Information about this animal model: Mouse Model for TB research